Cure51 is a TechBio company co-founded by leading international oncology centres, including Institute Gustave Roussy, Centre Léon Bérard and Charité. We are the first company in the world investigating on a global scale why a minority of patients achieve exceptionally long survival, while most others do not, despite receiving similar treatments. By analyzing the biology of these exceptional survivors, we aim to uncover insights that can lead to the development of drugs capable of eradicating cancer.

Our focus is on patients with the deadliest cancers, including metastatic pancreatic ductal adenocarcinoma, IDH wild-type glioblastoma, and extensive small cell lung cancer, where life expectancy is typically just 7–15 months. Yet, 3–6% of patients with these cancers survive 3–5 years or more without a clear medical explanation — these are the outliers. We aim to understand why these outliers defy the odds and live significantly longer. Understanding the biology behind their remarkable survival could reveal new oncology targets and pave the way for innovative therapies.

Cure51’s reverse-engineering approach aims to identify the key pathways and genes responsible for the “Outlier phenotype” and leverage this knowledge to induce similar outcomes in typical tumors through novel therapeutic targets. Our mission is to make every patient an outlier.